AZD1775 + pemetrexed + carboplatin

This combination consists of **AZD1775** (also known as adavosertib or MK-1775), a **potent selective small molecule inhibitor of WEE1 tyrosine kinase**, co-administered with **pemetrexed**, an antifolate antineoplastic agent, and **carboplatin**, a platinum-based chemotherapeutic agent. AZD1775 inhibits WEE1, leading to abrogation of the G2/M checkpoint and enhanced sensitivity of tumor cells (especially p53-deficient) to DNA-damaging agents such as pemetrexed and carboplatin. The combination is investigated primarily in advanced solid tumors, including ovarian cancer and other p53-mutated cancers, aiming to exploit synthetic lethality and increase chemotherapeutic efficacy[1][5].

Brand names

adavosertib

Other names

WEE1 inhibitor + pemetrexed + carboplatin